Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
October 15 2018 - 10:22AM
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading
developer of therapeutics that target galectin proteins, today
announced that management will participate in the upcoming ROTH
Capital Battle of the NASH Thrones Investor Conference being held
October 17 at the Park Hyatt Hotel in New York City.
About Galectin Therapeutics Galectin
Therapeutics is dedicated to developing novel therapies to
improve the lives of patients with chronic liver disease and
cancer. Galectin’s lead drug (GR-MD-02) is a carbohydrate-based
drug that inhibits the galectin-3 protein which is directly
involved in multiple inflammatory, fibrotic, and malignant
diseases. The lead development program is in non-alcoholic
steatohepatitis (NASH) with cirrhosis, the most advanced form of
NASH related fibrosis. This is the most common liver disease and
one of the largest drug development opportunities available
today. Additional development programs are in treatment of
severe atopic dermatitis, moderate-to-severe plaque psoriasis, and
in combination immunotherapy for advanced melanoma and other
malignancies; advancement of these additional clinical programs is
largely dependent on finding a suitable partner. Galectin seeks to
leverage extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. Additional
information is available at www.galectintherapeutics.com.
Contacts:Jack Callicutt, Chief Financial
Officer(678) 620-3186ir@galectintherapeutics.com.
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Oct 2023 to Oct 2024